Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Core system code doesn't move at quite the same pace as the latest vibe coders, and thankfully so, as it needs to be stable, ...
Shareholders are getting serious about sustainability. by Robert G. Eccles and Svetlana Klimenko Most corporate leaders understand that businesses have a key role to play in tackling urgent challenges ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.